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Abstract: Monkeypox is a rare self-limiting viral zoonosis (a virus transmitted to humans from animals) 
with symptoms in humans similar to those seen in the past in smallpox patients, although less severe. 
Monkeypox virus (MPV) causes monkeypox disease. The virus belongs to the family: Poxviridae; 
Subfamily: Chordopoxvirinae; Genus: Orthopoxvirus. MPV was first identified in laboratory monkeys at 
State Serum Institute in Copenhagen, in 1958.  The first human case of MPV was detected in 1970, in 
Zaire (Democratic Republic of the Congo—DRC) after smallpox eradication in the country. The primary 
disease symptoms include: Demonstration of  characteristic prodromal illness for 2 days before the 
onset of rash with fever, malaise, and lymphadenopathy by most patients. Almost 90% of patients 
infected with monkeypox develop lymphadenopathy, which is the key feature distinguishing human 
monkeypox from smallpox. Typical monkeypox rash begins as maculopapular lesions of 2-5 mm in 
diameter; the rash becomes generalized in distribution in most cases, spreading in centrifugal pattern. 
Skin lesions progress from papules to vesicles, and pustules followed by umbilication, scabbing, and 
desquamation over a period of 14-21 days. Skin lesions are observed on mucous membrane, in the 
mouth, on tongue, and on genitalia. Monkey pox disease mortality rate in Africa is about 10%. The most 
recent outbreak of Monkeypox disease occurred in 2017, in Nigeria. This paper is a comprehensive 
review of the: pathology, pathogenesis, epidemiology, signs and symptoms, diagnoses and prevention of 
monkeypox disease. 
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 1 Introduction   
Monkeypox is an orthopoxvirus that is closely related to smallpox and exhibits a similar pustular rash 
[1]. Monkeypox virus (MPV) is the pathogenic agent for Monkey pox disease. The consequences range 
from asymptomatic infections to severe, fatal illness. Monkeypox disease is a smallpox-like viral 
infection caused by a virus of zoonotic origin [2].The virus belong to the family: Poxviridae; subfamily: 
Chordopoxvirinae; and genus: Orthopoxvirus. Morphologically, the virion: enveloped shaped, slightly 
pleomorphic; dumbbell-shaped core with lateral bodies [3]. Between 140-260 nm in diameter by 
220-450 nm in length.MPV is a nucleic acid: linear, double-stranded DNA virus; genome length: ~197 
kb in length bp.MPV is resistant to common phenolic disinfectants. But it can be inactivated with polar 
lipophilic solvents, such as chloroform, and at low pH [4]. Complete inactivation of the closely related 
vaccinia virus occurs in 2-3 hours at 60°C or within minutes following exposure to 20 nMcaprylate at 
22°C; however, MPV is more resistant than vaccinia to solvent-detergent treatment [5]. It has an 
incubation period of 7-17 days (mean of 12 days).Other members of the Orthopox genus include 
Variolavirus (smallpox virus), Vaccinia virus (smallpox,vaccine virus), Ectromelia virus, Camelpox 
virus, and Cowpox virus[6]. 
 The identification of monkeypox virus is based on biological characteristics and endonuclease 
patterns of viral DNA [7]. In contrast to smallpox, monkeypox virus can infect rabbit skin and can be 
transmitted serially by intra-cerebral inoculation of mice. The four orthopox viruses that may infect 
man produce macroscopically characteristic lesions on the inoculated chorioallantoic membrane of an 
embryonated chicken egg [8]. The maximum or 'ceiling' temperature at which the viruses can 
proliferate in the chorioallantoic membrane differs for monkeypox and smallpox [8]. These viruses 
differ also in the ability to multiply in different tissue culture cells. However, at present the clearest 
results are obtained by the endonuclease restriction patterns of the virus DNA [9]. Some genetic 
variability has been noted between monkeypox viruses isolated from West and Central African regions 
[10]. Genome studies have revealed strong evidence regarding monkeypox virus being a non-ancestral 
to variola virus. This may be important in view of the fear expressed by some researchers that variola 
might again evolve from monkeypox virus [11]. In the pre-molecular era, significant efforts were made 
to distinguish the four viruses by serological reactions. These were delicate studies, since the viruses 
share most antigens [11, 12, and 13]. Some results were obtained using absorbed sera in agar gel 
diffusion tests, but they were rapidly superseded by the studies on biological characteristics and DNA 
restriction patterns [12]. The development of relatively specific antigens has been extremely useful for 
serological surveys in human and animals. In the field, rapid presumptive diagnosis of infection caused 
by viruses belonging to the orthopoxvirus group is necessary, as is differentiation from chickenpox, as 
confusion is possible on clinical grounds [14]. For this purpose, it is recommended that scabs of the 
lesions are sent, without transport medium, to the diagnostic laboratory. Electron microscopic 
examination of this material will allow the differentiation of Orthopox and Herpes viruses [15]. 
Poxviruses can be detected in more than 95% of the scabs, whereas varicella-zoster virus could be 
detected in only half of the material from cases of chickenpox, meaning that electron microscopy 
negative specimens are very unlikely to be monkeypox [16]. 
1.1 Etiology  
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Monkeypox results from infection by the monkeypox virus, a member of the genus Orthopoxvirusin the 
family Poxviridae (subfamily Chordopoxvirinae) [3]. Two clades of monkeypox viruses, the West 
African and Congo Basin viruses have been identified. The Congo Basin viruses are more virulent [5]. 
Monkeypox virus is closely related to some other orthopox viruses such as variola (smallpox) virus, and 
it cannot be distinguished from these viruses in some laboratory tests [17]. 
1.2Classification and Characterization of Monkeypox Virus  
Poxviruses are the largest vertebrate viruses known, infecting humans, and other vertebrates (species of 
sub-family Chondropoxvirinae), and arthropods (species of sub-family Entemopoxvirinae) [18]. There 
are around 70 known species of pox viruses spread among 28 genera and two sub-families (the 
Chordopoxvirinae and the Entomopoxvirinae). The virions contain a linear double-stranded 
deoxyribonucleic acid (dsDNA) genome and enzymes that synthesize messenger ribonucleic acid 
(mRNA). They multiply in the cytoplasm of the host cells [19].  
 The Chordopoxvirinae consists of around ten genera including the genera which are 
genetically and antigenetically related [20]. The genus Orthopox virus comprises camelpox, cowpox, 
ectromelia, monkeypox, racoonpox, skunkpox, taterapox, Uasingishu (pox virus of Horses in Kenya), 
vaccinia, variola and volepox. African swine fever viruses were also known to share some properties of 
the poxviruses [21].  
 Many poxviruses are associated with a specific vertebrate species, which indicates that the 
transmission of these viruses occurs preferentially among a specific vertebrate species [22]. 
Nevertheless, accidental transmission into a different vertebrate species can occur [22]. There was no 
resultant clinical-pathological condition noted in the infected host to be further maintained in this 
'aberrant' species. The orthopox viruses which can infect humans include variola, vaccinia, cowpox and 
monkeypox viruses [18]. Variola virus is a virus which only infects humans and the Vaccinia virus is a 
vaccine strain that does not exist in nature and is used to treat small pox. Vaccinia virus originated in the 
18th Century from an unknown vertebrate species [23]. 
1.3 Historical background and Epidemiology of Monkeypox Disease 
Monkeypox is typically found in the Central and West African rain forests. MPV was first identified in 
1958, in a group of sick laboratory monkeys (Macacacynomolgus),at State Serum Institute in 
Copenhagen. The first known human case occurred in1970 in the Equateur province of Zaire (now 
known as the Democratic Republic of Congo (DRC) when a 9-year-old boy developed smallpox like 
illness which was confirmed as human monkey pox by the World Health Organization [24]. 
Monkeypox was limited to the rain forests of central and western Africa until in June 2003, when the 
first cases in the Western Hemisphere were reported [21]. The source of this single outbreak was small 
mammals imported from West Africa. Prairie dogs housed in pet stores in close proximity to these 
infected small mammals became infected and transmitted the infection to humans [ 21].Multiple 
persons were identified in the Midwestern United States who had developed fever, rash, respiratory 
symptoms, and lymphadenopathy following exposure to ill pet prairie dogs (a rodent of Cynomys 
species) infected with the monkeypox virus. The only outbreak of human monkeypox reported outside 
Africa occurred in the United States in 2003. The virus entered North America in exotic African rodents 
imported as pets, and spread to pet prairie dogs, which were highly susceptible to infection [25]. This 
virus subsequently infected approximately 70 people who had been in contact with these animals [25].  
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 A direct contact or exposure with ill, prairie dogs (a group of herbivorous burrowing rodents), 
showing signs of profuse nasal and ocular discharge, dyspnoea, lymphadenopathy, and muco-cutaneous 
lesions was noted among the cases reported. Another interesting observation noted among those cases 
was the presence of a common animal distributor where prairie dogs were housed or transported along 
with African rodents from Ghana [26].  
 People living in or near the forested areas may have indirect or low-level exposure, possibly 
leading to subclinical infection. The disease is rare and only known to be indigenous to the rain forests 
of western and central Africa. The first known human case came after the eradication of smallpox, 
possibly because of the subsequent unmasking of the infection [27]. Surveillance reports from 
1981-1986 documented 338 cases in the DRC (out of a 1982 estimated population of 5 million). In the 
1996-1997 outbreaks in the DRC, the attack rate was 22 cases per 1000 population. Human infection 
with monkey pox has not been reported in West Africa since 1978. However, monkeypox continues to 
exhibit a robust emergence in the DRC, with sporadic occurrences of disease in neighboring countries 
[2]. In 2003, 11 cases and 1 death were reported from the DRC and 10 cases with no deaths were 
reported from Sudan in 2005[28]. In United States, no cases occurred until the late spring 2003 outbreak 
in the Midwestern states. Between May 16 and June 20, 2003, 71 suspected cases of monkeypox were 
investigated. Mortality/morbidity rash burden, hospitalization rates and illness severity (a global score 
incorporating degree of incapacitation, need for nursing care and rash burden) were used to define 
human disease [28]. 
In the African epidemics, 90% of the patients were children younger than 15 years. In the US outbreak, 
of the confirmed cases in 2003 (n = 35), 11 patients were younger than 18 years and 24 were older. 
Although the highest age-specific incidences and the greatest number of cases occur among persons 
younger than 15 years, a trend toward increasing incidence among persons aged 15-30 years has been 
seen in recent years [25]. It has been hypothesized that cessation of smallpox vaccination may be a 
factor in the increasing incidence in this age group. An annual crude incidence rate of human monkey 
pox of 0.63/10,000 population was inferred. Those at high risk were young unvaccinated children 
(especially boys) and adult women. Approximately one third of the infections were estimated to be 
sub-clinical [19]. The increase in cases was ascribed to the effect of the civil war which had led to 
increased hunting for forest animals that carry monkey pox, particularly squirrels. With changes in 
lifestyle due to increasing urbanization, and intensified agricultural activities replacing hunting and 
trapping, the chances of contracting monkey pox, either from the primary reservoir or intermediate 
hosts, will decrease [11]. 
 Several documented outbreaks have occurred in Central and West Africa close to tropical rain 
forests where humans have frequent contact with infected animals. The 2003 outbreak in the US, as a 
result of virus introduction through infected exotic pets, resulted in 37 laboratory-confirmed cases. No 
cases have been reported in the US since that outbreak. In Africa, the reported mortality rate is about 10% 
among patients with disease [19, 28].Genomic sequencing of monkeypox strains isolated from the 
America, western and central Africa’s, has noted the existence of two distinct clades of the virus. The 
isolates from the United States were found to be identical with the western African strains. The clinical 
course of the disease among people infected with the western African strain was observed to be milder 
with minimum human-to-human transmission as compared to those infected with isolates from central 
African region [25].  
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Table 1     Timeline of Human Cases of Monkeypox Disease 
Period Cases reported 
1958-1969 Sporadic outbreaks in captured monkeys (Zoo research centre) 
Europe, USA 
1970 First human case (9years old boy, Zaire) DRC 
1970-1980                        
Sierra Leone 
59 cases: Zaire (DRC), Cameron, Cote d’ivoire, Liberia, Nigeria, (Most [80% 48 
cases]) were from Congo (DRC). 
1981-1986   404 cases 386 (95%) from Congo (DRC) 
1987-1995                             13 case (1987: 6 case, 1990: 1 case, 1991; 5 cases, and 1992; 1 case) 
from: Cameroon (1) Gabon (100, Congo (2). 
1993-1995 No case reported 
1996-1997 511 case in 54 villages with peaks of transmission in August 
1996 (51 Cases), March 1997 (40 cases) and August 1997 (71 cases) 
2003 70 cases (USA) 
2017 74 cases (Nigeria) 
Source [29, 24] 
1.4 Common Human Exposure Routes and Transmission modes 
Common human exposure routes includes: respiratory, percutaneous, and permucosal exposures to 
infected monkeys, zoo animals, prairie dogs, and humans. Likelihood of secondary transmission 
include: direct contact with body fluids, respiratory droplets, or with virus-contaminated objects, such 
as bedding or clothing. Period of human-to-human transmission is during the first week of the rash [30]. 
Longest chain of documented human-to-human transmission was five generations (four serial 
transmissions). African rodents are the major vector and reservoir of infection. It is a zoonotic virus 
with primary transmission believed to occur through direct contact with infected animals or possibly by 
ingestion of their inadequately cooked flesh. Inoculation may be from cutaneous or mucosal lesions on 
the animal, especially when the skin barrier is compromised secondary to bites, scratches, or trauma. 
Transmission can also occur from animal reservoirs from Western Africa (prairie dogs, rabbits, rats, 
mice, squirrels, dormice, monkeys, porcupines, gazelles). Additionally, direct cutaneous (skin-to-skin) 
or respiratory contact with an animal or person who is infected can transmit the infection [31].  
2 Risks factors to MPV disease, and Likelihood of Clinical Disease 
In Africa, people coming in contact with infected animals. A close association with wild animals 
leading to bites, and consumption of bush meat could be potential risk factors to acquire monkepox 
virus infection [29]. Risk factors are very lower in the US, based on animal import controls established 
in 2003.  The likelihood of the disease include a high percentage of exposed individuals develop 
clinical disease. In addition, serological evidence of infection has been reported in about 3% of 
asymptomatic household contacts of MPV symptomatic individuals studied between 1980 and 1984 in 
DRC [24]. 
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 3 Hosts and Reservoirs  
Although rodents are believed to be the major reservoir in Africa, a 2010 study reaffirmed that several 
species of forest-dwelling rodents are at risk of developing Orthopox virus (including monkey pox) 
infection [22]. Serological surveys suggest that many animals are infected with MPV under natural 
conditions, including squirrels, non-human primates, and rats. Several epidemiological studies from the 
Democratic Republic of Congo have implicated squirrels (especially Funisciurus anerythrus) 
inhabiting agricultural areas as primary candidates to sustain viral transmission among people in nearby 
settlements. In one environmental survey, Funisciurus spp. squirrels had a higher rate of MPV 
seropositivity (24%) than other animals that were tested, including Heliosciurus spp. squirrels (15%) 
and primates (8%) [12]. A subsequent seroprevalence study done as part of the investigation of the 
outbreak in February 1997, in the Democratic Republic of Congo showed even higher positivity rates in 
these squirrels (39—50% in Funisciurus spp. and 50% in Heliosciurus spp. squirrels) . In addition, 16% 
of Gambian giant rats tested in this study had serological evidence of MPV exposure [32]. The infection 
of a rabbit (family Leporidae) after exposure to a diseased prairie dog at a veterinary clinic confirmed 
the transmissibility of the virus between mammal species common in North America. Little is known 
about co-infection with MPV and HIV[19].  
 Two genera of African squirrels, Funisciurus spp. (rope squirrels), and Heliosciurus spp. (sun 
squirrels), have high seroprevalence rates, and have been suggested as possible maintenance hosts or 
vectors in Africa [26] 
4 Symptoms and diagnosis  
4.1 Primary Disease Symptoms  
In humans, the signs and symptoms of monkeypox are similar to smallpox, but usually milder. 
Approximately 12 days after exposure, symptoms of fever, headache, backache, muscle aches and 
extreme tiredness occur. Swelling of the lymph nodes also occurs with monkeypox[28]. One to three 
days (or longer) after the fever starts, a rash begins. This rash develops into raised bumps filled with 
fluid. The bumps progress to become crusts and scabs before they fall off. Most patients demonstrate 
characteristic prodromal illness for 2 days before the onset of rash with fever, malaise, and 
lymphadenopathy [28, 25]. Almost 90% of patients infected with monkeypox develop 
lymphadenopathy, which is the key feature distinguishing human monkeypox from smallpox. Typical 
monkeypox rash begins as maculopapular lesions of 2-5 mm in diameter; the rash becomes generalized 
in distribution in most cases, spreading in centrifugal pattern. Skin lesions progress from papules to 
vesicles, and pustules followed by umbilication, scabbing, and desquamation over a period of 14-21 
days [25]. Skin lesions are observed on mucous membrane, in the mouth, on tongue, and on genitalia. In 
addition to skin lesions, extracutaneous manifestations, such as secondary skin and/or soft-tissue 
infection (19% of cases), pneumonitis (12%), ocular complications (4%-5%), and encephalitis (<1%), 
were also observed [19]. No hemorrhagic form of monkeypox has been described in humans. Among 
individuals with smallpox vaccination history, the rash is milder and more likely to be pleomorphic. 
Pediatric patients are more likely to be hospitalized in an intensive care unit [19].Typical clinical 
presentation of human monkeypox in a child is presented in Fig.1. 
 The clinical presentation of human monkeypox was described primarily among children and 
adolescents identified in central and West African regions. The disease was characterized as a viral 
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prodrome fever with chills, headache, myalgias, and back pain lasting for 1–3 days, followed by a 
maculopapular exanthematous eruption. The rash was predominantly monomorphic with a centrifugal 
distribution, progressing to vesicular, pustular, and finally developing crusts during a 2– 3-week period. 
Clinicians should consider monkeypox in people with fever, cough, headache, myalgias, rash or lymph 
node enlargement within 3 weeks after contact with prairie dogs or giant Gambian rats [5].  
 Monkeypox viral infection can cause a syndrome clinically like smallpox but was noted to be 
less infectious and clinically milder. Fever could be the first symptom (usually 38.5-40.5°C). The 
febrile illness may often be accompanied by chills, drenching sweats, severe headache, backache, 
myalgia, malaise, anorexia, prostration, pharyngitis, shortness of breath, and cough (with or without 
sputum). Lymphadenopathy might appear within 2-3 days after the fever in most cases [4]. In the 2003 
outbreak, 47% of patients had cervical lymphadenopathy, with nodes measuring several centimeters in 
diameter [8]. In the exanthematous stage, most infected people develop a rash within 1-10 days after the 
onset of fever. The rash often starts on the face and then spreads to the rest of the body, and could persist 
for 2-4 weeks until all lesions have turned to crusts. Encephalitis with immunoglobulin M (IgM) was 
observed in the cerebrospinal fluid [11]. 
 In the exanthematous stage, within a body region, lesions evolve synchronously over 14-21 
days, like the development of lesions with smallpox. However, unlike smallpox, skin lesions may 
appear in crops [11]. In contrast to smallpox, the lesions do not have a strong centrifugal distribution. 
Lesions progress from macules to papules to vesicles and pustules; the face, the trunk, the extremities, 
and the scalp are involved. Lesions may appear both in covered and uncovered areas. Lesions may be 
seen on the palms and the soles. Necrosis, petechiae, and ulceration may be features and pruritus may 
also occur. Pain is unusual, and, if it occurs, it is often associated with secondary bacterial infection. In 
patients who have been previously vaccinated against smallpox, a milder form of disease occurs. In 
children, the lesions may appear as non-specific, erythematous papules that are 1-5 mm in diameter and 
suggestive of arthropod bite reactions [33].  
4.2 Diagnosis of MPV diseases  
The geographic location of the patient is important in the diagnosis of monkeypox, since the disease is 
known to occur mostly in remote villages, in the tropical African rain forests [34]. It is also important to 
differentiate the lesions of monkeypox from that of small pox and chicken pox during clinical diagnosis. 
The latter appears in successive crops so that lesions at various stages of development are visible at any 
time. In contrast with smallpox, the distribution of chickenpox is 'centripetal' with more lesions on the 
trunk than on the face and extremities. Identification of infection with monkeypox virus is complex due 
to its similarities between smallpox virus, and, varicella-zoster viruses [35].  
 The characteristic skin lesions are suggestive of monkeypox, and histopathology provides 
supportive evidence. The diagnosis can be confirmed by virus isolation or polymerase chain reaction 
assay (PCR)[36]. Monkeypox virus can be recovered in mammalian cell cultures, and may be identified 
using PCR followed by restriction fragment– length polymorphism (RFLP) analysis or sequencing. 
Monkeypox-specific PCR assays are available in some laboratories, and a DNA oligonucleotide 
microarray can identify this virus rapidly and specifically. PCR can also be performed directly on 
clinical samples [37].  
 No FDA-licensed blood donor screening test exists [12]. Currently, CDC uses cell culture or 
chick chorioallantoic membrane isolation in conjunction with a DNA-based assay for the diagnosis of 
orthopox virus infection. Several DNA-based tests and sequencing are useful. Serological tests are not 
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useful for the diagnosis of acute infection [19].For definitive diagnosis, scabs can be forwarded to a 
reference laboratory where electron microscopy may confirm the presence of an Orthopox virus and 
differentiate this virus from varicella virus. The virus can be cultured in tissue culture and identified by 
DNA restriction analysis [6].  
 A viral culture should be obtained from an oropharyngeal or nasopharyngeal swab. A skin 
biopsy specimen of the vesiculopustular rash or a sample of the roof of an intact vesiculopustular should 
be analyzed. Tissue for PCR of DNA sequence-specific for the monkeypox virus may be obtained [31]. 
Paired sera for acute and convalescent titers may be analyzed. Serum collected more than 5 days for 
IgM detection or serum collected more than 8 days after rash onset for IgG detection was most efficient 
for the detection of the monkeypox virus infection [1]. A Tzanck smear can help differentiate 
monkeypox from other non-viral disorders in the differential diagnosis. However, a Tzanck smear does 
not differentiate a monkeypox infection from smallpox or herpetic infections [26].  
 Monkey pox cases were confirmed based on virus isolation or detection of the virus by 
polymerase chain reaction (PCR) from a clinical specimen (skin biopsy or throat culture). Individuals 
who presented with fever and rash within 21 days of exposure to monkey pox and had serum positive 
for orthopox immunoglobulin M (IgM), but did not have culture- or PCR- positive clinical specimens, 
were classified as having a probable case of infection [4]. The most reliable clinical sign differentiating 
monkeypox from smallpox and chickenpox is enlarged lymph nodes, especially the sub mental, 
submandibular, cervical, and inguinal nodes. Regarding exanthema, nonspecific lesions and 
inflammation of the pharyngeal, conjunctival, and genital mucosae have been observed [3].  
 Morand and Morand [10], observed that although clinical recognition of monkeypox is the 
first step in diagnosis, the definitive diagnosis can however only be done in the laboratory where the 
virus can be identified by a number of different tests which include:  
i. Enzyme-linked immunosorbent assay (ELISA) 
ii. Antigen detection tests 
iii. Polymerase chain reaction (PCR) assay 
iv. Virus isolation by cell culture 
The swabs of lesions, fluid samples or crusts are most appropriate for laboratory. 
5 Treatment and Prevention 
5.1 Treatment  
There is no specific treatment for monkeypox other than supportive care to prevent complications [19]. 
In Africa, people who had previously received the smallpox vaccine had a lower risk of monkeypox. 
The Centers for Disease Control and Prevention (CDC)[25], developed guidelines explaining when 
smallpox vaccine should be used to protect against monkeypox. When a case of monkeypox has been 
confirmed, the investigators, veterinarians, animal control workers and healthcare personnel involved 
may be advised to receive the smallpox vaccine. 
 No proven treatment for humans but animal studies shows effectiveness of antiviral treatment 
either with cidofovir or with a related acyclic nucleoside phosphonate analog. In animals, treatment 
with antiviral compounds is more effective in reducing mortality than the therapeutic use of smallpox 
vaccine. The Centers for Disease Control and Prevention (CDC)[19] recommended smallpox 
vaccination within 2 weeks, ideally before 4 days, after a significant, unprotected exposure to a diseased 
animal or a confirmed human case. Data from the African outbreaks suggested that prior smallpox 
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vaccination confers 85% protection from monkeypox viral infection. Efficacy of vaccination was noted 
to be prolonged with protection noted even several years after vaccination, and the incidence of 
complications being reduced [11].  
 Multiple pathogen reduction steps used in the fractionation process have been shown to be 
robust in removal of enveloped viruses. Treatment with solvent-detergent and pasteurization has been 
effectively used for inactivation of vacciniavirus and may be useful for monkeypox. Nanofiltration of 
plasma may be effective in the removal of monkeypox virus [9]. 
5.2 Prevention 
Vaccinia immunization is approximately 85% effective in preventing human monkeypox disease, and 
CDC [19], recommends its use for exposed people up to 14 days after the exposure. Improved infection 
control measures, including the regular screening, and isolation of newly infected animals will certainly 
help in preventing outbreaks among animals. Better hygiene habits are warranted to avoid spreading of 
the virus on fomites which then become a source for newer infections [39]. Vaccination with vaccinia 
virus could be choice to protect animals. Because infections have been reported in Asian monkeys 
mixed with primates from Africa, care must be taken to house these species separately. Anyone who has 
been exposed to monkeypox virus should avoid contact with animals, particularly rodents and 
non-human primates, to stop transmitting the virus [40].  
 Avoid contact with prairie dogs or giant Gambian rats that appear ill. Prairie dogs with 
monkeypox had missing patches of fur, lesions on their skin, and respiratory symptoms (discharge from 
eyes or nose). Wash your hands thoroughly following any contact with sick animals. It is important that 
ill prairie dogs should not be released into the wild. If the prairie dog has a disease, it could infect wild 
prairie dogs [41].  
 During an outbreak, monkeypox viral spread may be controlled by quarantining (at least for 
six weeks from the date of the last exposure) the infected animals and tracing of their contacts. Areas 
where these animals have been kept should be cleaned and disinfected thoroughly. Although Vaccinia 
immunization has proven effective, in the prevention of monkeypox disease, general vaccination of 
people in the endemic areas is not recommended [42]. This is because human infection with monkeypox 
virus is a rare disease; no benefit would be derived from vaccination with Vaccinia virus. Furthermore, 
smallpox vaccination cannot be undertaken in populations with high prevalence of HIV infection 
because of the risk of serious complications [29]. 
The U.S. Centers for Disease Control and Prevention (CDC)[25], recommends disinfection of 
contaminated surfaces with 0.5% sodium hypochlorite or other EPA approved high level disinfectants. 
Incineration or autoclaving is appropriate for some contaminated materials. Burial without 
decontamination is not recommended. 
5.2.1 Prevention measures 
Nalca et.al. [44] and NCDC [29],enumerated important measures in MPV prevention to include: 
i. Preventing spread of the virus through restrictions on animal trade: Potentially infected animals 
should be isolated from other animals and placed into immediate quarantine. Animals that may 
have come in contact with an infected animal should be quarantined, handled with standard 
precautions and observed for monkeypox symptoms for 30 days. Isolate infected patients from 
others who could be at risk for infection. Avoid direct contact with animals that could harbor 
the virus including sick or dead animals especially in areas where monkeypox occurs. Avoid 
contact with any material that has been in contact with a sick animal. 
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ii. Reducing the risk of infection in people: During human monkeypox outbreaks, close contact 
with other patients is the most significant risk factor for transmission of infection. In the 
absence of specific treatment or vaccine, the only way to reduce infection in people is by raising 
awareness of the risk factors and educating people about the measures they can take to reduce 
exposure to the virus. Surveillance measures and rapid identification of new cases is critical for 
outbreak containment. 
iii. Controlling infection in health-care settings: Health-care workers caring for patients with 
suspected or confirmed monkey pox virus infection, or handling specimens from them, should 
implement standard infection control precautions. Samples taken from people and animals with 
suspected monkey pox virus infection should be handled by trained staff working in suitably 
equipped laboratories. 
iv. Maintaining general hygiene: Always wash hands with soap and water after contact with 
infected animals. Regular hand washing after caring for, or visiting sick people. Wear 
protective equipment (hand gloves, etc) when taking care of ill people and thoroughly cook all 
animal products before eating. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Typical clinical presentation of human monkeypox in a 7years old child of Sankuru District, Democratic 
Republic of Congo 
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